– Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile – – Controlled IL-12 in combination with PD-1 inhibitor has favorable safety profile and initial survival data are encouraging – – Data again consistent
Dr. David Mauney stepping down as President; Remains a consultant to the Company BOSTON , May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr.
BOSTON , May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 ,
BOSTON , May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 , at
– Regulatory discussions with FDA advance Ziopharm TCR-T IND process – – Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® ; Controlled IL-12 clinical data update at ASCO 2020 – – Work restrictions at NCI and MD Anderson impacting clinical trials; Ziopharm
BOSTON , April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment
BOSTON , April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the first quarter ended March 31, 2020 .
– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial milestones and data readouts in 1H20 – – Company to host conference call and webcast today at 4:30
BOSTON , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Barclays Global Healthcare Conference in Miami on Wednesday, March 11, 2020
BOSTON , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended December
